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Abstract
Background: Cervical cancer is one of the most common tumors affecting women with a disproportionate
mortality occurring in developing countries. Despite the high prevalence of cervical cancer and cervical neoplasia in
Gabon, few studies have been performed to evaluate the prevalence and determinants of HPV infection in this
country. The aim of this study was to determine the HPV prevalence and distribution in a population of Gabonese
women with normal cytology and cervical abnormalities.
Methods: A total of 200 cervical samples collected in the “Departement d’Anatomie et de Cytologie Pathologiques”
of the “Faculté de Medecine et des Sciences de la Santé” in Libreville, Gabonwere analyzed. Cytological status was
classified according to Bethesda 2001. Nested polymerase chain reaction (PCR) using consensus degenerate PCR
primers (MY09/11 and GP5+/6+) was performed for the detection of HPV DNA and HPV typing was done by DNA
sequencing.
Results: Cytological analysis showed that 87 % of women had normal cytology (n = 174/200). Among the 26
women with cytological abnormalities, predominance (61.5 %; 16/26) of low grade squamous intraepithelial lesion
(LSIL) was found and no cervical cancer case was detected. Overall, HPV DNA was detected in 60 % of women
(120/200). With respect to the cytological status, HPV DNA was found in 57.5 % of women with normal cervix and
76.9 % of women with abnormal cytology. HPV genotyping was performed on 114 HPV positive cases and revealed
the presence of 11 distinct genotypes: 16, 18, 33, 31, 56, 6, 66, 70, 35, 45 and 81. The high risk type HPV 16 was the
most common genotype found in all cytological categories. Six HPV positive samples could not be typed by DNA
sequencing, probably due to multiple HPV infection. Evaluation of possible risk factors showed that HPV infection
was related positively with number of sexual partners (≥3, OR = 2.3; 95 % CI, 1.3–4.3), history of sexually transmitted
infection (Chlamydia, OR = 1.9; 95 % CI, 1.01–3.4) and marital status (single, OR = 2.0; 95 % CI, 1.1–3.5).
Conclusion: The prevalence of HPV infection among Gabonese women is high. Our findings highlight the need to
set up a national program to fight cervical cancer, combining Pap smear test and HPV testing, to improve cervical
cancer prevention in Gabon.
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Background
Human Papillomavirus (HPV) is the most common
sexually transmitted infection worldwide [1, 2] and sev-
eral clinical and epidemiological studies have identified
this virus as a causative agent of cervical cancer (CC)
development [3–5]. More than 40 HPV types infecting
the genital tract of women have been identified and se-
quenced [6, 7]. Some HPV types, like 6 and 11, are cause
of benign condylomas (low risk group; LR) while a wider
number of types (HPV 16, 18, 31, 33, 35, 39, 45,51, 52,
56, 58, 59, 68) has been proved to be involved in cervical
carcinogenesis (high risk group; HR) [8]. The overall
prevalence of HPV in women with CC has been re-
ported to be as high as 99.7 % [3]; and, HPV 16 and
HPV 18 are the most frequently reported HPV types,
causing approximately 70 % of CC cases worldwide [9].
Worldwide, a good management of CC depends on
an early detection of the disease and efficient prophy-
lactic vaccines. Early detection of the disease depends
of the use of Pap smear screening test which has largely
contributed in decreasing mortality by CC. However, a
number of problems with cytology persist and have
been well described elsewhere, including sensitivity,
quality of samples and the subjectivity of the reading of
slides leading to greater number of interpretive errors
[10].Recent molecular biological techniques such as
HPV-DNA testing, have been found to be effective
HPV screening methods and may facilitate early detec-
tion of CC in developing regions. HPV DNA testing for
cancer-associated HPV DNA offers a very interesting
option for early detection of cervical lesions and is now
accepted as a viable and validated approach in the man-
agement of women with equivocal cytological findings
and those without cytological abnormalities [11]. In-
deed, women with normal cytology infected by a HR
HPV have approximately 100-fold increased risk of
developing cervical cancer compared to uninfected
women [12].
On the other hand, prophylactic vaccination repre-
sents an interesting primary prevention measure against
CC. Currently, two HPV-preventive vaccines (Gardasil®
and Cervarix®) are widely used. However, the impact of
this preventive measure in different geographical regions
will be related to the prevalence of the genotypes 16 and
18 in the different population.
In Gabon, like other African countries, CC is the most
common cancer among women. The age-standardized
incidence of CC is 19.9 per 100 000 women and the
mortality is 8.4 per 100 000 women [13]. Little is known
about HPV prevalence and distribution among Gabonese
women. The present study examined the prevalence and
distribution of HPV genotypes in Gabonese population
and evaluated whether certain factors were associated with
HPV infection.
Results
The cytological results of the 200 samples showed that
87 % had a normal cytology (174/200). Among the 26
women with cytological abnormalities, 8 (30.8 %) were
atypical squamous cell of undetermined significance
(ASCUS); 16 (61.5 %) were low grade squamous sntrae-
pithelial lesion (LSIL); and, only 2 cases (7.7 %) were classi-
fied as high grade squamous intraepithelial lesion (HSIL).
In these women, no cytology indicating CC was observed.
The presence of amplifiable DNA was confirmed in all
200 samples by β-globin PCR; and, all samples were ad-
equate for further analysis. Results of HPV detection
and typing are reported in Table I. Overall, 60 % of par-
ticipating women harbored HPV DNA (120/200). More-
over, HPV DNA was detected in 57.5 % of women with
normal cytology (100/174) and 76.9 % of the women
with abnormal cytology (20/26). Distribution of HPV ac-
cording to cervical abnormalities showed that HPV
DNA was found in 50 % of ASCUS (4/8), 87.5 % of LSIL
cases (14/16), and in all the HSIL cases (2/2).
HPV genotyping by DNA sequencing was only pos-
sible on 114 HPV positive cases and revealed the pres-
ence of 11 distinct genotypes and mostly with high
oncogenic potential (Table 1). Six HPV positive samples
could not be typed. HPV HR DNA was detected in
83.3 % (80/96) of HPV positives women with normal
cytology and in 77.8 % (14/18) of HPV positives abnor-
mal cervices, whereas LR HPV was detected in 16.7 %
(16/96) of women with normal cytology and in 22.2 %
(4/18) of women with abnormal cytology. The distribu-
tion of viral genotypes in all HPV positives samples
showed clearly the predominance of HPV 16 (59.6 %;
68/114). Moreover, HPV16 was detected in 58.3 % of
HPV positives normal cases (56/96) and 66.7 % of
women with abnormal cytology (12/18). Overall, the
other HR HPV 33, 31 and 56 were detected in 8.8 %
(10/114), 3.5 % (4/114), and 3.5 % (4/114)) respectively.
HPV 18, 35, 45, and 66 were detected in 1.8 % each
(2/114). Of particular interest, HPV45 was detected only
in cases with abnormal cytology. In this study, LR HPV
detected were HPV6, 70 and 81. HPV6 was detected in
14.6 % of HPV positives normal cases (14/96) and in
11.1 % of abnormal cytology HPV positives (2/18). HPV70
was detected only in normal cases (2.1 %; 2/96), whereas
HPV81 was detected only in 2 abnormal cytologies
(11.1 %).
HPV prevalence by age group is reported in Fig. 1.
HPV prevalence peaked among women <25 years of age
and ≥55 years of age. HR HPV prevalence was high
across all age groups and showed a slight decline among
older women, aged >55 years who present the highest
proportion of LR HPV.
The relationship between HPV positivity and risk fac-
tors such as age, age of the first sexual intercourse,
Zoa Assoumou et al. Infectious Agents and Cancer  (2016) 11:2 Page 2 of 8
number of sexual partners during lifetime, cigarette
smoking, oral contraceptive use, marital status, history
of sexual transmitted infection (HIV and Chlamydia
Trachomatis) and parity was investigated (Table 2).
Statistical analysis showed a statistically significant
association between the presence of HPV infection and
number of sexual partners ≥ 3 during lifetime (OR = 2.3;
95 % CI, 1.3–4.3); being single (OR = 2.0; 95 % CI, 1.1–3.5)
and infection with Chlamydia trachomatis (OR = 1.9; 95 %
CI, 1.01–3.4).
Other risks such as age, parity, age of the first sexual
intercourse, oral contraceptive use, cigarette smoking,
had no statistically significant association with HPV in-
fection (p > 0.05).
Table 1 Distribution of HPV genotypes according to cytological diagnosis
All samples (n = 200) Normal cytology (n = 174) Abnormal cytology (n = 26)
ASCUS (n = 8) LSIL (n = 16) HSIL (n = 2) Total (n = 26)
Negative 80 (40.0) 74 (42.5) 4 (50.0) 2 (12.5) 0 (0.0) 6 (23.1)
Positve 120 (60.0) 100 (57.5) 4 (50.0) 14 (87.5) 2 (100) 20 (76.9)
Undetermined HPV types 6 (5.0) 4 (4.0) 2 (50.0) - - 2 (20.0)
Determined HPV types 114 (95.0) 96 (96.0) 2 (50.0) 14 (100) 2 (100) 18 (80.0)
HR HPV+ 94 (82.5) 80 (83.3) 2 (100) 10 (71.4) 2 (100) 14 (77.8)
LR HPV+ 20 (17.5) 16 (16.7) - 4 (28.6) - 4 (22.2)
HR genotypes
HPV 16 68 (59.6) 56 (58.3) 2 (100) 8 (57.1) 2 (100) 12 (66.7)
HPV 18 2 (1.8) 2 (2.1)
HPV 33 10 (8.8) 10 (10.4)
HPV 31 4 (3.5) 4 (4.2)
HPV 35 2 (1.8) 2 (2.1)
HPV 45 2 (1.8) 0 (0.0) 2 (14.3) 2 (11.1)
HPV 56 4 (3.5) 4 (4.2)
HPV 66 2 (1.8) 2 (2.1)
LR genotypes
HPV 6 16 (14.0) 14 (14.6) 2 (14.3) 2 (11.1)
HPV 70 2 (1.8) 2 (2.1)
HPV 81 2 (1.8) 0 (0.0) 2 (14.3) 2 (11.1)
The distribution of HPV genotypes in all cytological categories found is presented in this table
The number in bracket are the percentages
Fig. 1 Age specific prevalence of HPV DNA among Gabonese women studied
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Discussion
Worldwide, HPV testing for cancer-associated HPV
DNA is now accepted as a viable and validated option in
the management of women with equivocal cytology
findings; and, in the last few years, there has been an
increasing interest in using the HPV testing also in
cervical samples from asymptomatic women without
cytological abnormalities [14]. This strategy seems to
allow an early identification of populations at different
risk level for this neoplasia because of the close rela-
tionship between HPV infection and cervical cancer
development.
In Gabon, there is no national organized CC screening
program. However, some efforts are made to reduce the
prevalence of cervical cancer by organisation of screen-
ing campaigns in order to detect women with cervical
cancer disease or precancerous lesions for an early and
effective management. However, few data are available
on the prevalence of HPV in the Gabonese population
and distribution of HPV genotypes. Thus, the aim of this
work is to characterize HPV genotype circulating in
Gabon and highlight the interest of introducing HPV
testing in the global management of cervical cancer and
precancerous lesions.
Not surprisingly for a sub-Saharan Africa country, our
finding showed a high HPV prevalence (60 %). Indeed
comparable rates were also reported in Equatorial
Guinea (60 %) [15], in Conakry Guinea (51.5 %) [16], in
Table 2 Potential risk factors associated with HPV infection in the Gabonese women
Characteristics N HPV+ HPV- aOR (95 % CI) P
Age
< 25 18 14 (77.8) 4 (22.2) 1.8 (0.5–6.3) 0.4
25–34 32 18 (56.3) 14 (43.7) 0.6 (0.3–1.7)
35–44 44 22 (50.0) 22 (50.0) 0.5 (0.2–1.2)
45–54 64 38 (59.4) 26 (40.6) 0.7 (0.3–1.7)
> 55 42 28 (66.7) 14 (3.33) 1
Marital status
Single (Never married/Separated/Widowed) 90 62 (68.9) 28 (31.1) 2.0 (1.1–3.5) 0.02
Living with partner/Married 110 58 (52.8) 52 (47.2) 1
Age of the first sexual intercourse
< 18 120 70 (58.3) 50 (41.7) 0.8 (0.5–1.5) 0.6
≥ 18 80 50 (62.5) 30 (37.5) 1
Number of sexual partners during lifetime
< 3 61 28 (45.9) 33 (54.1) 1 0.007
≥ 3 139 92 (66.2) 47 (33.8) 2.3 (1.3–4.3)
Smoking
No 196 116 (59.2) 80 (40.8) 1 0.15
Yes 4 4 (100) 0 (0.0) 1.5 (1.1–2.1)
Oral contraception use
Yes 2 1 (50.0) 1 (50.0) 0.7 (0.04–11.0) 0.8
No 198 118 (59.6) 80 (40.4) 1
Parity
0 26 14 (53.9) 12 (46.1) 1 0.4
1–3 62 36 (58.1) 26 (41.9) 1.2 (0.5–3.0)
> 3 112 70 (62.5) 42 (37.5) 1.4 (0.6–3.4)
History of STI
No 126 68 (54.0) 58 (46.0) 1 0.03
Chlamydia trachomatis 70 48 (68.6) 22 (31.4) 1.9 (1.0–3.4)
HIV 4 4 (100) 0 (0.0) 7.7 (0.4–145.8)
Some risk factors of HPV infection were evaluated. This table provides information about the association found between HPV infection and some risk factors
among the Gabonese women studied
The number in bracket are the percentages
aAll the considered variables were used in a multivariate logistic regression analysis
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Kenya (44.3 %) [17] and in Nigeria (37 %) [18]. A pre-
vious study conducted by Si-Mohammed et al. [19] on
women of childbearing age living in Libreville-Gabon
reported the presence of HPV DNA in 46 % of cases. This
difference is probably due to the sensitivity of the method
used for HPV detection. In the previous Gabonese HPV
study, HPV DNA was detected by standard PCR using the
MY09/MY11 primer set, whereas a nested PCR using
MY09/11 and GP5+/6+ was used in our study. There is
evidencethat nested PCR is more sensitive and allows to
reduce false negative cases [20].
The overall prevalence of HR-HPV found in our study
was 82.5 % of HPV positive cases which is in agreement
with some reported datain two studies conducted in
Burkina Faso and in Benin [21, 22]. Moreover, HPV 16
was the most predominant genotype from HPV positives
samples representing 59.6 % of cases. Thisgenotype was
also the most prevalent in all cytological categories. This
finding well corroborate with previously reported results
from many parts of the world [23–25]. However, in
some African studies, HPV16 is not usually the predom-
inant genotype, as it was reported in Benin where
HPV16 ranked third after HPV59 and 35 [22], and in
Burkina Faso, where HPV 52, 35 and 58 were the most
prevalent genotypes [26].
To our knowledge, this is the first study providing in-
formation about HPV genotypes distribution in regard
to cytological status among Gabonese women. HPV
DNA was detected in 57.5 % of women with normal cy-
tology and many of them harbor HR HPV. These results
are alarming in comparison with the worldwide HPV
prevalence among women with normal cervical cytology,
reported to be 10.4 % [27]. In Africa, similar studies have
reported less prevalence, as it’s the case in Morocco
(15.8 %) [28] and in Benin (26.7 %) [22]. Variations be-
tween studies most likely reflect differences in the popu-
lation studied with respect to risk factors for exposure to
HPV [29]. Moreover, the high prevalence of HPV in
women with normal cytology could be explained by the
low sensitivity of the Pap smear test. Indeed, the quality
of sampling and the subjectivity of the reading of slides
generate a high rate of false negative results, ranging
from 20 to 45 % [10, 30, 31].
For women with cervical abnormalities, HPV was
found at a high rate of 76.9 %. HPV DNA was detected
in 87.5 % of LSIL cases and in all the HSIL cases. HPV
16 was found in 57.1 % of the LSIL and, it was the
unique genotype found in HSIL cases. These findings
highlight the fact that HPV prevalence increased with
the severity of cervical lesions and HPV 16 has a greater
capacity than the other genotypes to persist longer in
the cervix and induce cervical alterations [32, 33].
In this study, 6 HPV positive cases could not be typed.
These specimens could very probably harbor multiple
infections and therefore could not be typed by DNA se-
quencing. DNA sequencing technique has been facing
limitation when the specimen harbors multiple geno-
types. Other genotyping approach would be used to
determine the exact HPV types in theses specimens, like
PCR-dot blot hybridization with specific probes or re-
verse line blot assays including the Linear Array HPV
genotyping assay (LA), INNO-LiPA HPV Genotyping
Extra (LiPA) and the reverse hybridization assay (RH)
[34] in our future studies.
Previous studies have showed that age-standardized
HPV prevalence varied more than 10-fold between pop-
ulations [35]. HPV prevalence peaked in younger women
and decline with age in Nigeria [18] and United States
[36], however; a second peak was found in older women
in Mexico [37] and Senegal [38]. Other countries such
as Kenya [39] and Ethiopia [40] exhibited a high HPV
prevalence across all age groups. In this study, high
peaks of prevalence were found in women < 25 years and
women ≥ 55 years old. The high HPV prevalence among
younger women may coincide with the initiation of
sexual activity [37]. Moreover the high HPV prevalence
among older women may be explained by HPV per-
sistence and/or new incident infections due to changing
sexual behavior and age-related changes of mucosal
biology and immune competence [40].
Some risk factors have been identified to increase the
risk of having an HPV infection and acting in conjunc-
tion with HPV to induce cervical cancer, such as age,
parity, oral contraceptive, cigarette smoking, age of first
sexual intercourse, marital status, and history of sexual
transmitted infections(STI) such as Chlamydia tracho-
matis and HIV [41, 42]. Indeed, some studies reported
that the presence of Chlamydia trachomatis raises the
acquisition and the persistence of HPV infection [43, 44]
and seems to facilitate the penetration of HPV and the
progress of cervical lesions by interfering in the im-
munological responses [45]. Women living with HIV are
also at increased risk for HPV infection [46]. In our
study, no statistically significant association between
HPV infection and the other risk factors such as age of
participants, age of sexual first intercourse, and parity
were found. However, statistically significant association
was found between HPV infection and number of sexual
partner during lifetime, history of STI, and marital sta-
tus.This finding highlights that only risk factors related
to sexual components are associated with HPV infection,
and therefore can reflect the sexual behaviors change in
Gabonese population.
Considerable efforts have been made to set up a
prophylactic vaccination strategy to prevent against HPV
infection and persistence. Thus, characterization of HPV
types circulating in Gabon is of a great interest and is an
essential component for the future application of
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prophylactic vaccines. However, other studies have to be
conducted for better characterization of HPV distribu-
tion and dissemination in Gabon, including the follow
up ofHPV positive women to evaluate the persistence/
clearance of HPV, evaluation of others risk factors of
HPV transmission such as the husband’s sexual behavior
as well as knowledge of Gabonese women about cervical
cancer and screening, and acceptance of HPV vaccine.
Conclusion
Despite the low number of participants, our study con-
firms the high prevalence of HPV infection in Gabon.
Moreover, a broad spectrum of HPV distribution was
found in women with normal cytology. These findings
highlight that in addition to Pap smear, HPV testing
should be considered, and will offer a significant oppor-
tunity for the Gabonese National Health Program to
control cervical cancer disease and save women lives.
These data can also help in the future to monitor the
impact of vaccination in Gabon.
Methods
Study population and sample collection
A total of 200 participants were recruited between January
and June 2012 among women screened for cervical cancer
in the “Departementd’ Anatomieet de Cytologie-
Pathologiques” of the “Faculté de Medecine et des
Sciences de la Santé” in Libreville, Gabon. The reason of
these women for seeking care was the recommendation of
their doctor after some gynecological problems such as
pelvic pain, vaginal discharge or pruritus. The women par-
ticipating in the study ranged in age from 19 to 67 years,
the mean age was 43.78 years. The majority of participants
(63 %) were undergoing cervical cancer screening for the
first time. All participants were to complete question-
naires, including socio-demographic characteristics such
as age, occupation, marital status, and parity; and an as-
sessment of their medical and sexual histories: the age of
first sexual activity, number of sexual partners during life-
time, antecedent of STI, cigarette smoking, oral contra-
ceptive use and the previous pap smears testing.
Each participant underwent a gynecological examin-
ation and collection of two samples of exfoliated cells.
The first sample was usedfor cytology diagnosis that was
done in the Anatomy Department and Pathological
Cytology of the “Faculté de Medecine et des Sciences de
la Santé”, Libreville-Gabon. Cytological diagnosis was
done in turnby two anatomy-pathologists (one after the
other) and the final conclusion was taken by consensus
according to Bethesda system 2001 [47]. The second
sample was suspended in the ThinPrep preservative
solution and stored at −20 °C, then routed to the
Virology and Microbiology Laboratory in the “Faculté
des Sciences et Techniques de Mohammedia” in Morocco,
for the molecular study.
The study was approved by Ethical Committees of the
“Ministère de la Santé de Libreville; N°00287/MS/SG”,
and written informed consent was obtained from each
study subject.
DNA isolation
After a brief centrifugation at 12 000 g for cells recuper-
ation, a lysis buffer (SDS 5 %, Tris- HCl 0.5 M pH 8.0,
EDTA 0.1 M and NaCl 2.5 M) containing proteinase K
(10 mg/ml) was added. DNA was isolated using standard
phenol chloroform method and ethanol precipitation.
Then, DNA was resuspended in ultrapure water and
stored at −20 °C until use.
HPV detection and typing
To evaluate the efficiency of the extraction, integrity of
specimen and absence of PCR inhibitors, all extracted
DNA were subject to an amplification of β-globin refer-
ence gene using the primers pair PCO4/GH20 [48].
HPV detection and typing was carried out by nested
PCR using the L1 consensus primers MY09/11 and
GP5+/6+ [49] and DNA direct sequencing [50]. The MY
and GP+ primers amplified respectively a fragment of 450
and 150 bp. PCR reactions were performed in a total
volume of 25 μl of the reaction mixture containing
10 mM of dNTP, 2.5 mM of Mgcl2, 0.2 U of GoTaq DNA
polymerase, and 10 μM of MY orGP+ primers in 1X Taq
polymerase buffer. For the GP+ PCR, 2 μl of the MY PCR
products was used as template.PCR amplification was per-
formed in a Perkin Elmer 2400 GeneAmpR® PCR thermal
Cycler (Scientific Support, Inc, Hayward, CA), and was
started with an initial denaturation step (95 °C for
10 min), followed by 40 cycles of 95 °C for 1 min,
annealing temperature (55 °C for MY primers and 48 °C
for GP+ primers) for 1 min and 72 °C for 1 min; a final
extension of 7 min at 72 °C was performed. For every re-
action, ultrapure water was used as a negative control and
DNA extracted from SiHa cell line was used as positive
control. PCR products were analyzed on a 2 % agarose gel
stained with Ethidium bromide and visualized by UV
light.
HPV genotyping was performed by DNA sequencing.
The PCR products were purified using the ExoSaP-IT
clean up system (USB, USA) and the sequencing reac-
tion was performed using GP6+ primer as the sequen-
cing primerwith the BigDye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA,
USA) on an ABI 3130 XL DNA analyzer (Applied
Biosystems, Foster City, CA, USA) according to manu-
facturer’s protocol.
The sequences were analyzed by MEGA software ver-
sion 6.0.5 (www.megasoftware.net). The BLAST server
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(http://www.ncbi.nlm.nih.gov/blast/) was used to match
all sequences available in GenBank database. At least
90 % identities matching between the query and subject
sequences were required for genotyping [50].
Statistical analysis
Data were analyzed using Epi info7 software (available in
www.cdc.gov). Chi-square of pearson and Fisher exact
tests were used when appropriate. To examine some risk
factors associated with HPV infection among Gabonese
women; all the considered variables were used in a
multivariate logistic regression analysis. Odds ratio (OR)
with 95 % confidential interval (CI) was used to evaluate
the strength of an association. The significance level was
considered when p < 0.05.
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